45 results about "Patient tolerance" patented technology

The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component compnsimg a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.

The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.

This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and / or to relieve constipation.

This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

This disclosure describes systems and methods for conducting and terminating spontaneous breathing trials on patients receiving mechanical ventilation. The disclosure describes a novel spontaneous breathing trial manager for a medical ventilator with rapid initiation and continuous monitoring of a patient's tolerance of the spontaneous breathing trial and displaying of that tolerance as a function of time, which provides for bedside adjustment of the spontaneous breathing trial parameters and automatic termination of a spontaneous breathing trial based on a time interval expiration or poor patient tolerance of the SBT.

This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

The invention discloses treatment of diabetes mellitus by taking insulin PEGylation derivative as an active component, which is characterized in that a drug delivery mode of single injection can be changed, and the patient tolerance is increased. After PEGylation of insulin, the renal clearance is reduced, the enzymolysis speed is reduced, the retention time of insulin in human body is increased, the drug delivery cycle is prolonged, and the treatment cost is reduced.

The invention provides use and a preparation method of vaginal thermosensitive gel. The use is the use of the vaginal thermosensitive gel in the preparation of medicaments for treating vaginitis including bacterial vaginitis, mycotic vaginitis, mycoplasmal vaginitis, trichomonas vaginitis and senile vaginitis. The vaginal thermosensitive gel of the invention has a pH value in accordance with a vaginal environment, high patient tolerance and long in-vivo duration of more than 20 hours and therefore can reduce dosing frequency, improve patient compliance, strengthen the treatment effect of the medicaments and reduce toxic and side effects. In addition, the temperature of the gel is mild, so the gel has high liquidity before entering bodies and becomes solid after entering the bodies and the administration is convenient and sanitary.

A method of solubilizing a selective inhibitor active agent of cyclo-oxigenase-2 (COX-2), such as meloxicam, and a method of preparing an ophthalmic solution from the solubilized meloxicam for the treatment of distinct ocular affections are described. The invention also refers to an aqueous ophthalmic solution resulting from the method, said ophthalmic solution being characterized by its safety, innocuousness and efficiency in the treatment of the patient. The new aqueous ophthalmic solution is characterized in that its pharmaceutical value is found in the use of a vehicle of easy access which not only permits the solubility of meloxicam, but which also favors a greater patient tolerance to the treatment of distinct affections of the eye and the patient's post-surgical recovery.

The certified doctor in United States, use pentobabital sodium as the hypnotic to refrain central nervous system. Pentobabital sodium can be patience to the body after two weeks, and the effect decrease half, and have lingering effects and remain effects. The making method and pharmacological activity about the six kinds of plants and sodium pentobarbital's synergistic action wares are gaven patent. Under the cautious and strict conditions, extract the plant ingredients, absorb them by WLD resin, separate and purify them, and use the finger mark atlas quantity to make sure that the end product poise and stabilize. Six plant compound wares have sedate, hypnotize and synergy pentobabital sodium, anti-penfourzopol. The clinical use proved the reliability. It is safe and compensatory to the pentobabital sodium. It solves the hypnotic's tolerance and addiction. It solves the problem, which is expected to conquer for a long time.

The invention belongs to the technical field of medicine preparation, and discloses a pharmaceutical composition containing a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) analogue and a dipeptidyl peptidase-4 (DPP-4) inhibitor and a preparation method thereof. The composition can effectively prevent, retard and treat type II diabetes, especially can effectively control the blood glucose concentration, and also can be used for treating diseases related to rising of the blood glucose concentration. In addition, the composition can reduce the use dosage of the GLP-1 analogue and the DPP-4 inhibitor, so as to effectively reduce side effects of the GLP-1 analogue and the DPP-4 inhibitor and improve the patient tolerance level.

The invention provides a protein polypeptide medicine duplex microsphere and a preparation method thereof. The method comprises the following steps of S1, performing medicine loading on protein polypeptide medicine and chitosan in weak acidic solvents; obtaining a nanometer particle solution; sequentially performing film filtering and reduced pressure drying to obtain the medicine coated chitosannanometer particles; S2, under the effect of coupling agents, performing grafting reaction on the medicine coated chitosan nanometer particles and polylactic acid to obtain the protein polypeptide medicine duplex microsphere. The invention also provides an insulin duplex microsphere, which is prepared by the method. The insulin duplex microsphere has the advantages that the use is safer; the patient tolerance is better; the effect is longer; the medicine effect is more stable; the sudden release is obviously reduced.

Provided herein is an invention of a disposable adjunct developed to address limitations associated with oximetry sensor use: patient skin irritation and breakdown; compromised or interrupted display of data resulting from ambient light interference; costs incurred from replacing sensors with failed adhesion; and use of extra sensors for acute monitoring of multiple patient sites. This adjunct may be manufactured at a fraction of the cost of traditional oximetry sensors and can be retrofit to any existing sensor. Data aberrations caused by ambient light interference are reduced, utilizing a photo-opaque layer to prevent interference from above and restoring adhesion with a hydrocolloid adhesive layer to prevent interference from below. The hydrocolloid adhesive layer provides an alternative to relatively aggressive adhesives found on the majority of oximetry sensors, thereby improving patient tolerance through reduced skin irritation. Additional intermediate layers may also be provided.

The invention relates to a catheter with expansion bags. The catheter comprises a catheter body and the expansion locating bags arranged on the catheter body, and the expansion locating bags surroundthe end of the catheter body in a C-shaped major-arc structure; after the expansion locating bags are filled and expanded, the bag walls of the front ends of the expansion locating bags are flush withor exceed the front end of the end of the catheter body, a catheter cavity of the catheter body is a catheterization channel cavity, and a first catheterization inlet and a second catheterization inlet are formed in the end of the catheter body; the first catheterization inlet is formed in the side wall of the end of the catheter body and located in a C-shaped opening of the expansion locating bags, the second catheterization inlet is located in the front end of the end of the catheter body, the catheter wall of the catheter body is provided with a filling and water-injecting channel cavity,and the filling and water-injecting channel cavity is communicated with the expansion locating bags. The catheter is simple in structure, low in production cost and convenient to operate, and the situation that the bladder mucous membranes are damaged when the front end of the end of the catheter body is stimulated can be effectively avoided; meanwhile, smoothness of catheterization of the catheter body is guaranteed, and the safety of retaining the catheter body for a long term and the patient tolerance are improved.

The invention discloses a traditional Chinese medicinal composition for treating face hormone-dependent dermatitis. Face hormone-dependent dermatitis belongs to the drug poisoning field in traditional Chinese medicine science, hormones belong to products of excessive dryness and sweet warmness, and misuse and long-term use of hormones can cause toxic heat accumulation, skin dystrophy, and face blockage and blood spreading by pathogenic wind, heat and toxin. The traditional Chinese medicinal materials with effects of removing heat from the blood, nourishing yin, clearing away heat and toxic materials, moistening dryness, dispelling wind and arresting itching, including Lactuca indica, Ardisia faberi, Parnassia palustris, tubeflower viburnum herb, Hypericum japonicum, Rubia yunnanensis, Galium aparine, Rosa multiflora, Adina pilulifera and Caragana korshinskii, are decocted in water to obtain decoction. Through clinical trials, the total effective rate is 92%, the therapeutic effect is outstanding, no adverse reaction is caused during treatment course, and the patient tolerance is good.

The invention provides a method for treating children autism by cooperating virtual reality (VR), auditory stimuli and olfactory stimuli for individual difference between different patients. The method has the advantages of good patient tolerance, high matching degree and good treatment effect. A perilla extract and eugenol are screened from multiple aromatic extracts to serve as olfactory stimuliand have the advantages of mild aroma and good popularity among patients. The method adopts the perilla extract and the eugenol as the olfactory stimuli and is applicable to different autism patients.

Compounds for use in the treatment of heart disease include a superoxide scavenger and an organic nitrate or nitrite moiety. The compounds can be represented by the formula (A)n(B)m, in which A is a superoxide scavenger, B is an organic nitrate or organic nitrite moiety, and n and m are values between 1 and 8. These compounds do not suffer from the problem of patient tolerance that is associated with the use of conventional agents such as organic nitrates.

A method of treating patients, particularly for pain and / or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.

A device and method for the diagnosis and / or treatment of any one or more of hearing loss, tinnitus and hyperacusis. The device is configured with programming to enable a patient to select from one or more program blocks that establish sound amplification and sound generation functions and to control adjustment of sound amplification and / or generation within a range. A single device of the invention can be used to detect and / or resolve a plurality of conditions including hearing loss, tinnitus and hyperacusis. The acoustic modulator device of the present invention enables effective tinnitus treatment, effective hyperacusis treatment and effective treatment when both exist. The method also includes a graduated process for building patient tolerance to noise amplitude when the patient has hyperacusis including doing so to allow the patient to reach a tinnitus threshold point.

The invention provides a comfortable nasal and gastrointestinal nutrient canal. The comfortable nasal and gastrointestinal nutrient canal is of a hollow structure and comprises a thick tube part and a thin tube part, wherein the thick tube part and the thin tube part are connected through a joint part, a side opening is formed in the periphery of the front end of the thick tube part, an opening is formed in the top of the front end of the thick tube part, and a funnel connector is connected with the tail end of the thin tube part. The invention further provides a working method of the comfortable nasal and gastrointestinal nutrient canal. The thick tube part and the joint part are located below the pharyngeal of a patient, the thin tube part passes through the nasopharynx of the patient, and nutrient liquid enters the gastrointestinal portion of the patient via the funnel connector through the side opening and the opening in the front end of the thick tube part, so as to supply nutrients to the human body. The thin tube and thick tube two-section combination mode is adopted, the thin tube is used for the nasopharynx, the thick tube is adopted for the portion after the nasopharynx, in this way, tube blockage can be avoided, discomfort of the nasopharynx of the patient can be relieved, patient tolerance is high, and the patient can feel more comfortable.

The invention discloses a medicine for treating liver cancer, and a preparation method and application thereof. The medicine is prepared from the following raw materials in parts by weight: 13 to 21 parts of radix astragali seu hedysari, 15 to 25 parts of chlorogenic acid, 1 to 5 parts of carvone, and 7 to 15 parts of artemisinin. The preparation method comprises the steps of mixing the radix astragali seu hedysari and the artemisinin, adding deionized water with the mass being 5.8 times of the total mass of the radix astragali seu hedysari and the artemisinin, and carrying out ultrasonic treatment for 22 min at the temperature of 48 DEG C to prepare a mixture A; mixing the chlorogenic acid and the mixture A, and carrying out ultrasonic treatment for 8min to prepare a mixture B; mixing the carvone and the mixture B, carrying out ultrasonic treatment for 15min at the temperature of 55 DEG C, and stirring at the temperature of 60 DEG C until dry so as to obtain the medicine. The medicine provided by the invention is simple in preparation process, simple and easy to get the adopted raw materials, low in production cost, simple to take, and good in absorption effect without side effect, the survival time is prolonged, and the patient tolerance is good.

The invention discloses an injection of an oligoethylene glycol-modified docetaxel derivative having good anticancer effect, which contains the oligoethylene glycol-modified docetaxel derivative having a structure of a formula I, the oligoethylene glycol-modified docetaxel derivative is dissolved in a lipophilic medium, and dispersed in an aqueous phase through the action of a surfactant in termsof nanoparticles; or directly dispersed in the aqueous phase through the action of the surfactant in terms of nanoparticles; wherein R is an alkyl group of C1 to C5; and n = 1 to 10. The injection comprises a liposome agent, an emulsion and a micelle agent, and has the characteristics of low toxicity, drug loading and stability improvement, and targeted drug delivery, so that the anti-tumor therapeutic effect of the drug is improved, the toxicity is reduced, and the patient tolerance is increased.

The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises liquid oil, a pharmaceutically acceptable gelator, a pharmaceutically acceptable stabilizer and a pharmaceutically active ingredient. The pharmaceutical composition is especially suitable for development of pharmaceutical preparations with anesthesia and analgesic activity, and has more advantages compared with other sustained-release analgesic systems, for example, release of analgesic active ingredients is continuous and stable, injection administration can be achieved, the pharmaceutical composition is suitable for stable and convenient local administration, patient tolerance is good, and side effects are few.

The invention discloses a medicinal composition for improving the glucose tolerance of a patient and an application thereof. The composition consists of the following traditional Chinese medicine raw materials in parts by weight: 10-20 parts of celery seed, 20-40 parts of peanut shell, 16-32 parts of tangerine peel, 10-20 parts of corn stigma, 10-20 parts of Chinese wax gourd peel and 8-16 parts of cassia twig. The medicinal composition disclosed by the invention can obviously improve the glucose tolerance and slow down the glucose metabolism process of the patient; the glucose tolerance is effectively improved.

The invention discloses a traditional Chinese medicine composition for treating intestinal metaplasia and a preparation method thereof. The traditional Chinese medicine composition comprises active ingredients: 30-80 parts by weight of hedyotis diffusa, 8-15 parts by weight of rhizoma curcumae, 20-30 parts by weight of raw coix seed and 25-35 parts by weight of salvia chinensis. The traditional Chinese medicine composition for treating intestinal metaplasia as gastric precancerous lesion and adopting the four drugs for intestinal metaplasia has a scientific ratio, and the components can coordinate and promote each other and produce a synergistic effect. The traditional Chinese medicine believes that the traditional Chinese medicine pathogenesis of intestinal metaplasia as gastric precancerous lesion can be summarized as spleen and stomach weakness, and damp heat and blood stasis combination. The traditional Chinese medicine treatment utilizes the principle of strengthening body resistance and eliminating evil. The traditional Chinese medicine composition has effects of clearing away heat, removing toxins and resolving dampness, and promoting blood circulation, removing blood stasisand eliminating stagnation, simplifies the formula, accurately utilizes drugs, has a precise formula, can reverse the precancerous lesions of the gastric cancer, has a definite clinical effect, is easy to take, has good patient tolerance and prevents untoward effects in long term use. The traditional Chinese medicine preparation can promote standardized treatment with traditional Chinese medicines.

The invention discloses treatment of diabetes mellitus by taking insulin PEGylation derivative as an active component, which is characterized in that a drug delivery mode of single injection can be changed, and the patient tolerance is increased. After PEGylation of insulin, the renal clearance is reduced, the enzymolysis speed is reduced, the retention time of insulin in human body is increased, the drug delivery cycle is prolonged, and the treatment cost is reduced.